Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) Director William Waddill sold 9,000 shares of the company's stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $107.68, for a total value of $969,120.00. Following the completion of the sale, the director owned 7,825 shares in the company, valued at $842,596. The trade was a 53.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Protagonist Therapeutics Stock Up 3.8%
Protagonist Therapeutics stock opened at $109.79 on Friday. The company has a market capitalization of $7.06 billion, a P/E ratio of -60.66 and a beta of 1.85. The stock's 50 day moving average is $101.59 and its 200 day moving average is $93.11. Protagonist Therapeutics, Inc. has a twelve month low of $49.38 and a twelve month high of $111.45.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.55. The company had revenue of $56.37 million for the quarter, compared to the consensus estimate of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. As a group, equities analysts expect that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current year.
Analyst Ratings Changes
Several research firms recently weighed in on PTGX. Wedbush upped their price target on Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an "outperform" rating in a research note on Wednesday, May 6th. TD Cowen increased their target price on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Citigroup reiterated an "outperform" rating on shares of Protagonist Therapeutics in a research note on Wednesday, May 6th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Protagonist Therapeutics in a research note on Friday, May 15th. Finally, Truist Financial increased their target price on Protagonist Therapeutics from $110.00 to $121.00 and gave the company a "buy" rating in a research note on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Protagonist Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $115.21.
Check Out Our Latest Report on PTGX
Hedge Funds Weigh In On Protagonist Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. Farallon Capital Management LLC lifted its position in Protagonist Therapeutics by 0.4% during the third quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company's stock valued at $411,601,000 after purchasing an additional 24,000 shares in the last quarter. Vanguard Group Inc. lifted its position in Protagonist Therapeutics by 27.2% during the fourth quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company's stock valued at $472,832,000 after purchasing an additional 1,156,461 shares in the last quarter. State Street Corp lifted its position in Protagonist Therapeutics by 18.5% during the second quarter. State Street Corp now owns 3,207,543 shares of the company's stock valued at $177,281,000 after purchasing an additional 500,924 shares in the last quarter. Wellington Management Group LLP lifted its position in Protagonist Therapeutics by 66.2% during the fourth quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company's stock valued at $276,992,000 after purchasing an additional 1,262,977 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its position in Protagonist Therapeutics by 9.1% during the first quarter. Janus Henderson Group PLC now owns 2,891,527 shares of the company's stock valued at $304,866,000 after purchasing an additional 241,546 shares in the last quarter. 98.63% of the stock is currently owned by hedge funds and other institutional investors.
Protagonist Therapeutics Company Profile
(
Get Free Report)
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
